High blood pressure and chronic kidney disease are two major health problems that often occur together.
Each condition can make the other worse, creating a harmful cycle that becomes increasingly difficult to manage over time.
For millions of people worldwide, controlling blood pressure while protecting kidney function remains a constant challenge.
Researchers are now investigating a new experimental medication called baxdrostat that may help address both problems at the same time. Early findings suggest the drug could lower blood pressure and reduce signs of kidney damage, offering hope for patients who do not respond well to existing treatments.
The research was presented at the American Heart Association’s Hypertension Scientific Sessions 2025 and published in the Journal of the American Society of Nephrology.
To understand why this drug has attracted attention, it is important to know how the kidneys and blood pressure are connected. The kidneys are two bean-shaped organs that filter waste products and excess fluid from the blood. They also help regulate blood pressure, maintain the body’s fluid balance, and control levels of important minerals.
When the kidneys become damaged, their ability to perform these functions gradually declines. Waste products can build up in the bloodstream, and the body’s fluid balance can become disrupted. Over time, this can lead to serious complications affecting the heart, blood vessels, and other organs.
High blood pressure is one of the leading causes of kidney disease. When blood pressure remains elevated for many years, it places excessive strain on the tiny blood vessels inside the kidneys. This damage can reduce the kidneys’ ability to filter blood properly.
At the same time, damaged kidneys can make blood pressure rise even further. Because of this two-way relationship, people with chronic kidney disease often struggle to achieve healthy blood pressure levels, even when taking multiple medications.
One hormone that plays an important role in both conditions is aldosterone. This hormone helps the body regulate sodium and water levels. Under normal circumstances, aldosterone is necessary for maintaining healthy fluid balance.
However, when aldosterone levels become too high, the body retains more sodium and water than it needs. This increases blood pressure and may contribute to blood vessel damage and kidney scarring over time.
Baxdrostat was specifically developed to block the production of aldosterone. By lowering the amount of this hormone, researchers hope to reduce blood pressure while also protecting kidney tissue from further damage.
The study focused on people who had both chronic kidney disease and uncontrolled high blood pressure.
Many participants were already taking standard medications commonly used for these conditions, including ACE inhibitors or angiotensin receptor blockers, often called ARBs. These drugs can be very effective, but some patients continue to have high blood pressure despite treatment.
At the beginning of the study, participants had an average systolic blood pressure of 151 millimeters of mercury. The systolic number is the top number in a blood pressure reading and reflects the pressure inside arteries when the heart contracts. A reading above 140 is generally considered elevated and increases the risk of serious health problems.
Participants also showed evidence of significant kidney damage. On average, they had approximately 714 milligrams of albumin in their urine. Albumin is a protein that normally remains in the bloodstream. Healthy kidneys prevent most albumin from passing into urine. When large amounts appear in urine, it is a sign that the kidneys’ filtering system has been damaged.
The trial enrolled 195 participants. Of these, 192 were randomly assigned to receive either a lower dose of baxdrostat, a higher dose, or a placebo. A placebo contains no active medication and allows researchers to compare results fairly. Throughout the study, participants continued taking their regular medications.
After 26 weeks of treatment, the results were encouraging. Participants receiving baxdrostat experienced larger reductions in systolic blood pressure than those receiving the placebo. On average, blood pressure fell by an additional 8.1 points in the baxdrostat groups.
Although an 8-point reduction may sound modest, cardiologists consider this level of improvement clinically important. Even relatively small decreases in blood pressure can significantly lower the risk of heart attacks, strokes, heart failure, and further kidney damage over time.
Researchers also carefully monitored side effects. The most commonly reported issue was elevated potassium levels in the blood. This is a known concern with medications that affect hormone systems involved in blood pressure regulation.
About 41 percent of participants taking baxdrostat experienced higher potassium levels, although most cases were mild and manageable.
Serious adverse events were relatively uncommon. Approximately 9 percent of participants receiving baxdrostat experienced serious health events compared with 3 percent in the placebo group. Importantly, there were no deaths during the study, and researchers did not identify any unexpected safety concerns.
One of the most promising findings involved albumin levels. Participants taking baxdrostat had approximately 55 percent lower albumin levels in their urine than those receiving the placebo. This suggests the drug may help reduce kidney damage and potentially slow the progression of chronic kidney disease.
Dr. Jamie Dwyer, who led the study, said the findings indicate that baxdrostat may help interrupt the harmful cycle in which kidney disease and high blood pressure continuously worsen one another. By reducing aldosterone production, the medication may improve blood pressure control while also protecting kidney tissue.
Independent experts have also welcomed the research. Dr. Jordana Cohen of the University of Pennsylvania noted that people with chronic kidney disease are frequently underrepresented in clinical trials.
As a result, doctors often have fewer evidence-based treatment options available for these patients. She said it is encouraging to see research focused specifically on this high-risk group.
Baxdrostat has not yet been approved by the U.S. Food and Drug Administration, and larger studies are still underway. Researchers want to determine whether the benefits seen in this trial can be maintained over longer periods and whether the drug can meaningfully slow the progression of kidney disease.
If future studies confirm these findings, baxdrostat could become an important new treatment for people living with both chronic kidney disease and difficult-to-control high blood pressure.
For patients facing these challenging conditions, a medication that protects both the heart and kidneys could make a significant difference in long-term health outcomes and quality of life.
If you care about kidney health, please read studies about pesticide linked to chronic kidney disease, and this drug may prevent kidney failure in people with diabetes.
For more health information, please see recent studies about drug duo that may treat kidney failure, and results showing these vegetables may protect against kidney damage.
The study was published in the Journal of the American Society of Nephrology.
Copyright © 2026 Knowridge Science Report. All rights reserved.
